Certified Registered Nurse Anesthetist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lance Hudson

Nurse Anesthetist, Certified Registered Greenwood, SC Certified Registered Nurse Anesthetist

NPI 1760462634 CMS profile 10672163

1325 Spring St, Greenwood, SC 29646

Open in the dashboard

General payments

$4,218

293 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lance Hudson of Greenwood, SC is reported in the CMS Open Payments database as having received $4,218 across 293 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Anesthetist, Certified Registered profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $727 48
2024 General $777 52
2023 General $1,267 87
2022 General $913 62
2021 General $533 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Hudson
  • Nurse Anesthetist, Certified Registered median
  • Middle half of Nurse Anesthetist, Certified Registered
  • National median

In program year 2025, general payments to Lance Hudson were reported at $727. Among 25,681 Nurse Anesthetist, Certified Registered profiles paid that year, the median was $46 and the middle half received between $23 and $106.

Show as a table
Year Lance Hudson Nurse Anesthetist, Certified Registered median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $533 $34 $17–$77 $132
2022 $913 $35 $19–$82 $149
2023 $1,267 $38 $20–$90 $160
2024 $777 $42 $22–$96 $164
2025 $727 $46 $23–$106 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,141 108 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $975 58 payments
  3. Janssen Biotech, Inc. $434 24 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $391 23 payments
  5. QOL Medical, LLC $215 15 payments
  6. Merck Sharp & Dohme Corporation $212 15 payments
  7. Aimmune Therapeutics, Inc. $150 8 payments
  8. Lilly USA, LLC $126 7 payments
  9. Nestle HealthCare Nutrition Inc. $95 5 payments
  10. Ferring Pharmaceuticals Inc. $84 5 payments
  11. Other $396 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,218 293 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $694 40 payments
  2. MAVYRET $558 48 payments
  3. LINZESS $492 51 payments
  4. CREON $461 47 payments
  5. STELARA $401 22 payments
  6. ENTYVIO $336 20 payments
  7. TRULANCE $280 18 payments
  8. PLENVU $204 14 payments
  9. DIFICID $200 14 payments
  10. ZENPEP $153 8 payments
  11. Other $1,489 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$64,948

Medicare's payments for the services billed

Medicare patients

754

Average age 73

Services billed

809

423 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 26%
Ischemic heart disease 24%
Depression 24%
Chronic kidney disease 17%
Cancer 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $114
$114 — —
MAVYRET
  • AbbVie, Inc. $107
$107 — —
OMVOH
  • Lilly USA, LLC $98
$98 — —
CREON
  • AbbVie, Inc. $85
$85 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record